Enriched plasma derivative for advancement of wound closure and healing
AssigneeSerapharm Michael Stroetmann
InventorMichael Stroetmann
Life of this patent
Estimating the term…
Abstract
A preparation for accelerated hemostasis and optimized biochemical control of wound closure ("tissue adhesive") consists only of solid, powdery, biologically active constituents and contains 60 to 96% by weight of fibrinogen, which is largely liberated from cryo-insoluble globulin, 0.05 to 5% by weight of a fibrinolysis inhibitor, and 0.1 to 15% by weight of thrombin and/or prothrombin. For use, this enriched plasma derivative may be applied in the form of a dry, powdery mixture immediately and directly onto the wound or in the area of operation, respectively. Further application methods provide atomizing, spraying, or foaming of the powdery mixture by means of a propellant.
Claims13
An enriched plasma derivative for supporting wound closure and healing, containing 60 to 96% by weight of fibrinogen and 0.5 to 5% by weight of a fibrinolysis inhibitor, wherein
- (a) the fibrinogen is largely free from cryo-insoluble globulin;
- (b) the plasma derivative additionally contains 0.1 to 15% by weight of thrombin and/or prothrombin;
- (c) all components are present in biologically active, solid powdery form at temperatures of up to 56.degree. C.;
- and
- (d) these solid components are mixed with each other.
Dependencies are inferred from the claim text.